Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations

Bibliography

• HOSSAIN MA, GHANNOUM MA: New investigational antifungal agents for treating invasive fungal infections. Expert Opin. Invest. Drugs (2000) 9(8):1797-8813.
   PubMed Web of Science ®Google Scholar
• KONTOYIANNIS DP, HARE R, SOLOMON H et al.: Posaconazole is highly effective as a second-line agent in zygomycosis: summary of 91 cases. 45th International Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (16 – 19 December 2005).
   Google Scholar
• BARTROLI X: A clinical multicenter study comparing efficacy and tolerability between five single oral doses of albaconazole and fluconazole 150 mg single dose in acute vulvovaginal candidiasis. 45th International Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (16 – 19 December 2005).
   Google Scholar
• JOHNSON LB, KAUFFMAN CA: Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. (2003) 36(5):630-637.
   PubMed Web of Science ®Google Scholar
• GOTHARD P, ROGERS TR: Voriconazole for serious fungal infections. Int. J. Clin. Pract. (2004) 58(1):74-80.
   PubMed Web of Science ®Google Scholar
• PEARSON MM, ROGERS PD, CLEARY JD, CHAPMAN SW: Voriconazole: a new triazole antifungal agent. Ann. Pharmacother. (2003) 37(3):420-432.
   PubMed Web of Science ®Google Scholar
• COURTNEY R, PAI S, LAUGHLIN M, LIM J, BATRA V: Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. (2003) 47(9):2788-2795.
   PubMed Web of Science ®Google Scholar
• COURTNEY R, RADWANSKI E, LIM J, LAUGHLIN M: Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob. Agents Chemother. (2004) 48(3):804-808.
   PubMed Web of Science ®Google Scholar
• COURTNEY R, WEXLER D, RADWANSKI E, LIM J, LAUGHLIN M: Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. (2004) 57(2):218-222.
   PubMed Web of Science ®Google Scholar
• GRACELA DM, OLSEN SJ, MUMMANENI V et al.: Ravuconazole: multiple ascending oral dose study in healthy subjects. 40th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (17 – 20 September 2000).
   Google Scholar
• OLSEN SJ, MUMMANENI V, ROLAN P, NORTON I, GRASELA DM: Ravuconazole single ascending oral dose study in healthy subjects. 40th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (17 – 20 September 2000).
   Google Scholar
• GROLL AH, MICKIENE D, PETRAITIS V et al.: Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. J. Antimicrob. Chemother. (2005) 56(5):899-907.
   PubMed Web of Science ®Google Scholar
• PETRAITIENE R, PETRAITIS V, LYMAN CA et al.: Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (2004) 48(4):1188-1196.
   PubMed Web of Science ®Google Scholar
• BARTROLI J, TURMO E, ALGUERO M et al.: New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. J. Med. Chem. (1998) 41(11):1869-1882.
   PubMed Web of Science ®Google Scholar
• CAPILLA J, YUSTES C, MAYAYO E et al.: Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits. Antimicrob. Agents Chemother. (2003) 47(6):1948-1951.
   PubMed Web of Science ®Google Scholar
• DONNELLY JP, DE PAUW BE: Voriconazole – a new therapeutic agent with an extended spectrum of antifungal activity. Clin. Microbiol. Infect. (2004) 10(Suppl. 1):107-117.
   PubMed Web of Science ®Google Scholar
• PURKINS L, WOOD N, GHAHRAMANI P et al.: Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. (2002) 46(8):2546-2553.
   PubMed Web of Science ®Google Scholar
• HOFFMAN HL, RATHBUN RC: Review of the safety and efficacy of voriconazole. Expert Opin. Investig. Drugs (2002) 11:409-429.
   PubMed Web of Science ®Google Scholar
• TRIFILIO S, ORTIZ R, PENNICK G et al.: Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant (2005) 35(5):509-513.
   PubMed Web of Science ®Google Scholar
• HARIPRASAD SM, MIELER WF, HOLZ ER et al.: Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch. Ophthalmol. (2004) 122(1):42-47.
   PubMed Web of Science ®Google Scholar
• KRIETER P FB, MUSICK T: Pharmacokinetics and excretion of 14C posaconazole following oral administration in healthy male subjects. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (27 – 30 September 2002).
   Google Scholar
• EZZET F, WEXLER D, COURTNEY R et al.: Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet. (2005) 44(2):211-220.
   PubMed Web of Science ®Google Scholar
• GUPTA AK, LEONARDI C, STOLTZ RR, PIERCE PF, CONETTA B: A Phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J. Eur. Acad. Dermatol. Venereol. (2005) 19(4):437-443.
   PubMed Web of Science ®Google Scholar
• ESPINEL-INGROFF A: In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. (2003) 20(4):121-136.
   PubMedGoogle Scholar
• PFALLER MA, MESSER SA, BOYKEN L et al.: Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J. Clin. Microbiol. (2004) 42(7):3137-3141.
   PubMed Web of Science ®Google Scholar
• FUNG-TOMC JC, HUCZKO E, MINASSIAN B, BONNER DP: In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. (1998) 42(2):313-318.
   PubMed Web of Science ®Google Scholar
• RAMOS G, CUENCA-ESTRELLA M, MONZON A, RODRIGUEZ-TUDELA JL: In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J. Antimicrob. Chemother. (1999) 44:283-286.
   PubMed Web of Science ®Google Scholar
• CUENCA-ESTRELLA M, GOMEZ-LOPEZ A, MELLADO E, GARCIA-EFFRON G, RODRIGUEZ-TUDELA JL: In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates. Antimicrob. Agents Chemother. (2004) 48(8):3107-3111.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, HOLLIS RJ, JONES RN, DIEKEMA DJ: In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. (2002) 46(6):1723-1727.
   PubMed Web of Science ®Google Scholar
• LAVERDIERE M, RESTIERI C, HABEL F: Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of Etest and NCCLS reference methods. Int. J. Antimicrob. Agents (2002) 20(6):468-471.
   PubMed Web of Science ®Google Scholar
• TAWARA S, IKEDA F, MAKI K et al.: In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. (2000) 44(1):57-62.
   PubMed Web of Science ®Google Scholar
• UZUN O, KOCAGOZ S, CETINKAYA Y, ARIKAN S, UNAL S: In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob. Agents Chemother. (1997) 41(5):1156-1157.
   PubMed Web of Science ®Google Scholar
• ZHANEL GG, KARLOWSKY JA, HARDING GA et al.: In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob. Agents Chemother. (1997) 41(4):863-865.
   PubMed Web of Science ®Google Scholar
• BARTIZAL K, GILL CJ, ABRUZZO GK et al.: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41(11):2326-2332.
   PubMed Web of Science ®Google Scholar
• MULLER FM, KURZAI O, HACKER J, FROSCH M, MUHLSCHLEGEL F: Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis. J. Antimicrob. Chemother. (2001) 48(5):713-715.
   PubMed Web of Science ®Google Scholar
• OSTROSKY-ZEICHNER L, REX JH, PAPPAS PG et al.: Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. (2003) 47(10):3149-3154.
   PubMed Web of Science ®Google Scholar
• ZHANEL GG, KARLOWSKY JA, ZELENITSKY SA, TURIK MA, HOBAN DJ: Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents. Antimicrob. Agents Chemother. (1998) 42(9):2446-2448.
   PubMed Web of Science ®Google Scholar
• LAVERDIERE M, HOBAN D, RESTIERI C, HABEL F: In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J. Antimicrob. Chemother. (2002) 50(1):119-123.
   PubMed Web of Science ®Google Scholar
• VAZQUEZ JA, LYNCH M, BOIKOV D, SOBEL JD: In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. (1997) 41(7):1612-1614.
   PubMed Web of Science ®Google Scholar
• MARCO F, PFALLER MA, MESSER SA, JONES RN: Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbiol. Infect. Dis. (1998) 32(1):33-37.
   PubMed Web of Science ®Google Scholar
• MIKAMO H, SATO Y, TAMAYA T: In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J. Antimicrob. Chemother. (2000) 46(3):485-487.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, COFFMAN S: In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob. Agents Chemother. (1997) 41(4):763-766.
   PubMed Web of Science ®Google Scholar
• CHAVEZ M, BERNAL S, VALVERDE A et al.: In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J. Antimicrob. Chemother. (1999) 44(5):697-700.
   PubMed Web of Science ®Google Scholar
• ZAOUTIS TE, FORAKER E, McGOWAN KL et al.: Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children’s hospitals. Diagn. Microbiol. Infect. Dis. (2005) 52(4):295-298.
   PubMed Web of Science ®Google Scholar
• CUENCA-ESTRELLA M, RODRIGUEZ D, ALMIRANTE B et al.: In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002 – 2003. J. Antimicrob. Chemother. (2005) 55(2):194-199.
   PubMed Web of Science ®Google Scholar
• KRISHNARAO TV, GALGIANI JN: Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. (1997) 41(9):1957-1960.
   PubMed Web of Science ®Google Scholar
• UCHIDA K, NISHIYAMA Y, YOKOTA N, YAMAGUCHI H: In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J. Antibiot. (Tokyo) (2000) 53(10):1175-1181.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, DIEKEMA DJ, MESSER SA, HOLLIS RJ, JONES RN: In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob. Agents Chemother. (2003) 47(3):1068-1071.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, DIEKEMA DJ, RINALDI MG et al.: Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J. Clin. Microbiol. (2005) 43(12):5848-5859.
   PubMed Web of Science ®Google Scholar
• ESPINEL-INGROFF A: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. (1998) 36(10):2950-2956.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, JONES RN, DOERN GV et al.: International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn. Microbiol. Infect. Dis. (1999) 35(1):19-25.
   PubMed Web of Science ®Google Scholar
• CHRYSSANTHOU E, CUENCA-ESTRELLA M: Comparison of the antifungal susceptibility testing subcommittee of the European committee on antibiotic susceptibility testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J. Clin. Microbiol. (2002) 40(10):3841-3844.
   PubMed Web of Science ®Google Scholar
• MARCO F, DANES C, ALMELA M et al.: Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996 – 2001). Diagn. Microbiol. Infect. Dis. (2003) 46(4):259-264.
   PubMed Web of Science ®Google Scholar
• HEYN K, TREDUP A, SALVENMOSER S, MULLER FM: Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob. Agents Chemother. (2005) 49(12):5157-5159.
   PubMed Web of Science ®Google Scholar
• QUINDOS G, CARRILLO-MUNOZ AJ, AREVALO MP et al.: In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy (2000) 46(6):395-401.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, GEE S et al.: In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J. Clin. Microbiol. (1999) 37(3):870-872.
   PubMed Web of Science ®Google Scholar
• AREVALO MP, CARRILLO-MUNOZ AJ, SALGADO J et al.: Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J. Antimicrob. Chemother. (2003) 51(1):163-166.
   PubMed Web of Science ®Google Scholar
• BARCHIESI F, SCHIMIZZI AM, FOTHERGILL AW, SCALISE G, RINALDI MG: In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur. J. Clin. Microbiol. Infect. Dis. (1999) 18(4):302-304.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, DIEKEMA DJ, MESSER SA et al.: In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn. Microbiol. Infect. Dis. (2004) 48(2):101-105.
   PubMed Web of Science ®Google Scholar
• ERNST EJ, ROLING EE, PETZOLD CR, KEELE DJ, KLEPSER ME: In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother. (2002) 46(12):3846-3853.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, BOYKEN L et al.: Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J. Clin. Microbiol. (2004) 42(7):3142-3146.
   PubMed Web of Science ®Google Scholar
• GHANNOUM MA, OKOGBULE-WONODI I, BHAT N, SANATI H: Antifungal activity of voriconazole (UK-109,496), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model. J. Chemother. (1999) 11(1):34-39.
   PubMed Web of Science ®Google Scholar
• CACCIAPUOTI A, LOEBENBERG D, CORCORAN E et al.: In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob. Agents Chemother. (2000) 44(8):2017-2022.
   PubMed Web of Science ®Google Scholar
• CLEMONS KV, STEVENS DA: Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice. Antimicrob. Agents Chemother. (2001) 45(12):3433-3436.
   PubMed Web of Science ®Google Scholar
• CAPILLA J, ORTONEDA M, PASTOR FJ, GUARRO J: In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob. Agents Chemother. (2001) 45(9):2635-2637.
   PubMed Web of Science ®Google Scholar
• ESPINEL-INGROFF A: Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J. Clin. Microbiol. (2003) 41(1):403-409.
   PubMed Web of Science ®Google Scholar
• GUINEA J, PELAEZ T, ALCALA L, RUIZ-SERRANO MJ, BOUZA E: Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation. Antimicrob. Agents Chemother. (2005) 49(8):3495-3497.
   PubMed Web of Science ®Google Scholar
• MOORE CB, WALLS CM, DENNING DW: In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob. Agents Chemother. (2000) 44(2):441-443.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, HOLLIS RJ, JONES RN: Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother. (2002) 46(4):1032-1037.
   PubMed Web of Science ®Google Scholar
• NAKAI T, UNO J, OTOMO K et al.: In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy (2002) 48(2):78-81.
   PubMed Web of Science ®Google Scholar
• OAKLEY KL, MOORE CB, DENNING DW: In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob. Agents Chemother. (1998) 42(10):2726-2730.
   PubMed Web of Science ®Google Scholar
• DIEKEMA DJ, MESSER SA, HOLLIS RJ, JONES RN, PFALLER MA: Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol. (2003) 41(8):3623-3626.
   PubMed Web of Science ®Google Scholar
• SERRANO MDEL C, VALVERDE-CONDE A, CHAVEZ MM et al.: In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn. Microbiol. Infect. Dis. (2003) 45(2):131-135.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MARCO F, MESSER SA, JONES RN: In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. (1998) 30(4):251-255.
   PubMed Web of Science ®Google Scholar
• CHANDRASEKAR PH, CUTRIGHT J, MANAVATHU E: Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J. Antimicrob. Chemother. (2000) 45(5):673-676.
   PubMed Web of Science ®Google Scholar
• IMAI JK, SINGH G, CLEMONS KV, STEVENS DA: Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob. Agents Chemother. (2004) 48(10):4063-4066.
   PubMed Web of Science ®Google Scholar
• KIRKPATRICK WR, PEREA S, COCO BJ, PATTERSON TF: Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J. Antimicrob. Chemother. (2002) 49(2):353-357.
   PubMed Web of Science ®Google Scholar
• MILLER JL, SCHELL WA, WILLS EA et al.: In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob. Agents Chemother. (2004) 48(2):384-387.
   PubMed Web of Science ®Google Scholar
• YILDIRAN ST, SARACLI MA, FOTHERGILL AW, RINALDI MG: In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole. Eur. J. Clin. Microbiol. Infect. Dis (2000) 19(4):317-319.
   PubMed Web of Science ®Google Scholar
• MORERA-LOPEZ Y, TORRES-RODRIGUEZ JM, JIMENEZ-CABELLO T, BARO-TOMAS T: Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med. Mycol. (2005) 43(6):505-510.
   PubMed Web of Science ®Google Scholar
• PERKINS A, GOMEZ-LOPEZ A, MELLADO E, RODRIGUEZ-TUDELA JL, CUENCA-ESTRELLA M: Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J. Antimicrob. Chemother. (2005) 56(6):1144-1147.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, BOYKEN L et al.: Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. (2005) 43(5):2163-2167.
   PubMed Web of Science ®Google Scholar
• CHANDENIER J, ADOU-BRYN KD, DOUCHET C et al.: In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. Eur. J. Clin. Microbiol. Infect. Dis. (2004) 23(6):506-508.
   PubMed Web of Science ®Google Scholar
• PERFECT JR, COX GM, DODGE RK, SCHELL WA: In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother. (1996) 40(8):1910-1913.
   PubMed Web of Science ®Google Scholar
• HATA K, KIMURA J, MIKI H et al.: In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob. Agents Chemother. (1996) 40(10):2237-2242.
   PubMed Web of Science ®Google Scholar
• DANNAOUI E, MELETIADIS J, MOUTON JW, MEIS JF, VERWEIJ PE: In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother. (2003) 51(1):45-52.
   PubMed Web of Science ®Google Scholar
• MINASSIAN B, HUCZKO E, WASHO T, BONNER D, FUNG-TOMC J: In vitro activity of ravuconazole against zygomycetes, Scedosporium and Fusarium isolates. Clin. Microbiol. Infect. (2003) 9(12):1250-1252.
   PubMed Web of Science ®Google Scholar
• SUN QN, FOTHERGILL AW, McCARTHY DI, RINALDI MG, GRAYBILL JR: In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother. (2002) 46(5):1581-1582.
   PubMed Web of Science ®Google Scholar
• PAPHITOU NI, OSTROSKY-ZEICHNER L, PAETZNICK VL et al.: In vitro antifungal susceptibilities of Trichosporon species. Antimicrob. Agents Chemother. (2002) 46(4):1144-1146.
   PubMed Web of Science ®Google Scholar
• MELETIADIS J, MEIS JF, MOUTON JW et al.: In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob. Agents Chemother. (2002) 46(1):62-68.
   PubMed Web of Science ®Google Scholar
• CARRILLO AJ, GUARRO J: In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother. (2001) 45(7):2151-2153.
   PubMed Web of Science ®Google Scholar
• GONZALEZ GM, FOTHERGILL AW, SUTTON DA, RINALDI MG, LOEBENBERG D: In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med. Mycol. (2005) 43(3):281-284.
   PubMed Web of Science ®Google Scholar
• SERENA C, MARINE M, PASTOR FJ, NOLARD N, GUARRO J: In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula. J. Antimicrob. Chemother. (2005) 55(6):1020-1023.
   PubMed Web of Science ®Google Scholar
• LI RK, CIBLAK MA, NORDOFF N et al.: In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob. Agents Chemother. (2000) 44(6):1734-1736.
   PubMed Web of Science ®Google Scholar
• SUGAR AM, LIU XP: In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob. Agents Chemother. (1996) 40(5):1314-1316.
   PubMed Web of Science ®Google Scholar
• ESPINEL-INGROFF A: In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. (1998) 36(1):198-202.
   PubMed Web of Science ®Google Scholar
• GONZALEZ GM, TIJERINA R, NAJVAR LK et al.: In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob. Agents Chemother. (2002) 46(5):1352-1356.
   PubMed Web of Science ®Google Scholar
• ORTONEDA M, CAPILLA J, PASTOR FJ et al.: In vitro interactions of approved and novel drugs against Paecilomyces spp. Antimicrob. Agents Chemother. (2004) 48(7):2727-2729.
   PubMed Web of Science ®Google Scholar
• GOMEZ-LOPEZ A, MELLADO E, RODRIGUEZ-TUDELA JL, CUENCA-ESTRELLA M: Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. J. Antimicrob. Chemother. (2005) 55(3):312-316.
   PubMed Web of Science ®Google Scholar
• ZAAS AK, BOYCE M, SCHELL W et al.: Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J. Clin. Microbiol. (2003) 41(11):5233-5235.
   PubMed Web of Science ®Google Scholar
• DANNAOUI E, MEIS JF, LOEBENBERG D, VERWEIJ PE: Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother. (2003) 47(11):3647-3650.
   PubMed Web of Science ®Google Scholar
• AL-ABDELY HM, NAJVAR LK, BOCANEGRA R, GRAYBILL JR: Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana. Antimicrob. Agents Chemother. (2005) 49(5):1701-1707.
   PubMed Web of Science ®Google Scholar
• AL-ABDELY HM, NAJVAR L, BOCANEGRA R et al.: SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum (‘Ramichloridium mackenziei’). Antimicrob. Agents Chemother. (2000) 44(5):1159-1162.
   PubMed Web of Science ®Google Scholar
• LUTZ JE, CLEMONS KV, ARISTIZABAL BH, STEVENS DA: Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob. Agents Chemother. (1997) 41(7):1558-1561.
   PubMed Web of Science ®Google Scholar
• CLEMONS KV, MARTINEZ M, CALDERON L, STEVENS DA: Efficacy of ravuconazole in treatment of systemic murine histoplasmosis. Antimicrob. Agents Chemother. (2002) 46(3):922-924.
   PubMed Web of Science ®Google Scholar
• PERFECT JR, MARR KA, WALSH TJ et al.: Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. (2003) 36(9):1122-1131.
   PubMed Web of Science ®Google Scholar
• KULLBERG BJ, SOBEL JD, RUHNKE M et al.: Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet (2005) 366(9495):1435-1442.
   PubMed Web of Science ®Google Scholar
• OSTROSKY-ZEICHNER L, OUDE LASHOF AM, KULLBERG BJ, REX JH: Voriconazole salvage treatment of invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. (2003) 22(11):651-655.
   PubMed Web of Science ®Google Scholar
• ALLY R, SCHURMANN D, KREISEL W et al.: A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. (2001) 33(9):1447-1454.
   PubMed Web of Science ®Google Scholar
• HEGENER P, TROKE PF, FATKENHEUER G, DIEHL V, RUHNKE M: Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS (1998) 12(16):2227-2228.
   PubMed Web of Science ®Google Scholar
• HERBRECHT R, DENNING DW, PATTERSON TF et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. (2002) 347(6):408-415.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, PAPPAS P, WINSTON DJ et al.: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. (2002) 346(4):225-234.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, FINBERG RW, ARNDT C et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. (1999) 340(10):764-771.
   PubMed Web of Science ®Google Scholar
• PRENTICE HG, HANN IM, HERBRECHT R et al.: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol. (1997) 98(3):711-718.
   PubMed Web of Science ®Google Scholar
• MARR KA: Empirical antifungal therapy-new options, new tradeoffs. N. Engl. J. Med. (2002) 346(4):278-280.
   PubMed Web of Science ®Google Scholar
• POWERS JH, DIXON CA, GOLDBERGER MJ: Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. N. Engl. J. Med. (2002) 346(4):289-290.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, LEE J, DISMUKES CA: Decisions about voriconazole versus liposomal amphotericin B (correspondence). N. Engl. J. Med. (2002) 346(19):1499.
   PubMedGoogle Scholar
• JOHNSON JR, ULlMANN A, HEUSSEL CP et al.: Voriconazole versus liposomal amphotericin B for empirical antifungal therapy (correspondence). N. Engl. J. Med. (2002) 346(22):1745-1747.
   PubMedGoogle Scholar
• RAAD I, BRADSHER R, MORRISON V et al.: Posaconazole salvage therapy for invasive fungal infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (October 30 – November 2 2004).
   Google Scholar
• GREENBERG RN, HACHEM R, LANGSTON A et al.: Posaconazole therapy for refractory invasive zygomycosis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (14 – 17 September 2003).
   Google Scholar
• HACHEM RY, RAAD I, AFIF C et al.: An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SHC56592) in the treatment of invasive fungal infections refractory or intolerant to standard therapy. 40th Interscience Conference on Antimicrobial Agents and Chemptherapy, Toronto, ON, Canada (17 – 20 September 2000).
   Google Scholar
• PITISUTTITHUM P, NEGRONI R, GRAYBILL JR et al.: Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother. (2005).
   PubMedGoogle Scholar
• WALSH TJ, PATTERSON T, LANGSTON A et al.: Posaconazole for treatment of invasive aspergillosis in patients who are refractory to or intolerant of conventional therapy: an externally controlled blinded trial. Blood (2003) 102:105a-106a.
   Google Scholar
• SEGAL BH, BARNHART LA, ANDERSON VL et al.: Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin. Infect. Dis. (2005) 40(11):1684-1688.
   PubMed Web of Science ®Google Scholar
• BLUMER J, HARE R, KRISHNA G et al.: Efficacy of posaconazole salvage therapy in pediatric subjects with invasive fungal infections. 15th European Congress for Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark (2005).
   Google Scholar
• VAZQUEZ JA, NORTHLAND R., MILLER S et al.: Posaconazole compared to fluconazole for oral candidiasis in HIV-positive patients. 40th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (17 – 20 September 2000).
   Google Scholar
• NIETO L, NORTHLAND R, PITTISUTTITHUM P et al.: Posaconazole equivalent to fluconazole in treatment of oropharyngeal candidiasis. 40th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada (17 – 20 September 2000).
   Google Scholar
• RESTREPO A, CLARK B, GRAHAM DR et al.: Successful treatment of disseminated and acute pulmonary histoplasmosis with posaconazole. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (14 – 17 September 2003).
   Google Scholar
• DUPONT B, WEINBRECK P, BRUGIERE C, WINTER C, LAHOULOU R: Effect of posaconazole salvage therapy in five patients with zygomycosis. 15th European Congress for Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark (2005).
   Google Scholar
• DUPONT B: Pulmonary mucormycosis (zygomycosis) in a lung transplant recipient: recovery after posaconazole therapy. Transplantation (2005) 80(4):544-545.
   PubMed Web of Science ®Google Scholar
• GILMAN AL, SERRANO A, SKELLEY J, ZWICK D: Successful treatment of pulmonary zygomycosis with posaconazole in a recipient of a haploidentical donor stem cell transplant. Pediatr. Blood Cancer (2005)
   Google Scholar
• LEATHER HL, CORRELL TA, MEYER CL, SCHMALFUSS IM, WINGARD JR: Treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia. Clin. Adv. Hematol. Oncol. (2005) 3(10):773-777.
   PubMedGoogle Scholar
• VAZQUEZ JA: Review of treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia. Clin. Adv. Hematol. Oncol. (2005) 3(10):777-778.
   PubMedGoogle Scholar
• TOBON AM, ARANGO M, FERNANDEZ D, RESTREPO A: Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin. Infect. Dis. (2003) 36(11):1488-1491.
   PubMed Web of Science ®Google Scholar
• CHEN A, SOBEL JD: Emerging azole antifungals. Expert Opin. Emerg. Drugs (2005) 10(1):21-33.
   PubMedGoogle Scholar
• BEALE M Q-TF, BANHEGYI D, LI N, PIERCE PF: Randomized, double-blind study of the safety and antifungal activity of ravuconazole relative to fluconazole in esophageal candidiasis. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (22 – 25 September 2001).
   Google Scholar
• DENNING DW, GRIFFITHS CE: Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin. Exp. Dermatol. (2001) 26(8):648-653.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR, RAAD I, NEGRONI R et al.: Posaconazole long-term safety in subjects with invasive fungal infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (October 30 – November 2 2004).
   Google Scholar
• GROLL AH, WALSH TJ: Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev. Anti-Infect. Ther. (2005) 3(4):467-487.
   PubMedGoogle Scholar
• LEWIS J, ANSTEAD G, GRAYBILL J: Successful treatment of disseminated coccidioidomycosis (Coccidioides immitis) with posaconazole. 15th Congress of the International Society for Human and Animal Mycosis, San Antonio, USA (25 – 29 May 2003).
   Google Scholar
• NEGRONI R, HELOU S, PETRI N et al.: Successful posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera: a case report. 15th Congress of the International Society for Human and Animal Mycosis, San Antonio, USA (25 – 29 May 2003).
   Google Scholar
• AL-ABDELY HM, ALKUNAIZI A, AL-TAWFIQ JA et al.: Successful treatment of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with a new triazole, posaconazole (SCH 56592). 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, Scotland (10 – 13 May 2003).
   Google Scholar
• MELLINGHOFF IK, WINSTON DJ, MUKWAYA G, SCHILLER GJ: Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin. Infect. Dis. (2002) 34(12):1648-1650.
   PubMed Web of Science ®Google Scholar
• MOUDGAL VV, SOBEL JD: Antifungal drugs in pregnancy: a review. Expert Opin. Drug Saf. (2003) 2(5):475-483.
   PubMedGoogle Scholar
• TORRES HA, HACHEM RY, CHEMALY RF, KONTOYIANNIS DP, RAAD II: Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis. (2005) 5(12):775-785.
   PubMed Web of Science ®Google Scholar
• GOSBELL IB, TOUMASATOS V, YONG J et al.: Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses (2003) 46(5-6):233-236.
   PubMed Web of Science ®Google Scholar
• HOWDEN BP, SLAVIN MA, SCHWARER AP, MIJCH AM: Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur. J. Clin. Microbiol. Infect. Dis. (2003) 22(2):111-113.
   PubMed Web of Science ®Google Scholar
• STEINBACH WJ, SCHELL WA, MILLER JL, PERFECT JR: Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J. Clin. Microbiol. (2003) 41(8):3981-3985.
   PubMed Web of Science ®Google Scholar
• GERZENSHTEIN L, PATEL SM, SCARSI KK, POSTELNICK MJ, FLAHERTY JP: Breakthrough Candida infections in patients receiving voriconazole. Ann. Pharmacother. (2005) 39(7-8):1342-1345.
   PubMed Web of Science ®Google Scholar
• ALEXANDER BD, SCHELL WA, MILLER JL, LONG GD, PERFECT JR: Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation (2005) 80(6):868-871.
   PubMed Web of Science ®Google Scholar
• PAVIE J, LACROIX C, HERMOSO DG et al.: Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J. Clin. Microbiol. (2005) 43(9):4902-4904.
   PubMed Web of Science ®Google Scholar
• KONTOYIANNIS DP, LIONAKIS MS, LEWIS RE et al.: Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J. Infect. Dis. (2005) 191(8):1350-1360.
   PubMed Web of Science ®Google Scholar
• OREN I: Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin. Infect. Dis. (2005) 40(5):770-771.
   PubMed Web of Science ®Google Scholar
• VIGOUROUX S, MORIN O, MOREAU P et al.: Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin. Infect. Dis. (2005) 40(4):e35-e37.
   PubMed Web of Science ®Google Scholar
• LIONAKIS MS, KONTOYIANNIS DP: Sinus zygomycosis in a patient receiving voriconazole prophylaxis. Br. J. Haematol. (2005) 129(1):2.
   PubMedGoogle Scholar
• KOBAYASHI K, KAMI M, MURASHIGE N et al.: Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica (2004) 89(11):ECR42.
   PubMedGoogle Scholar
• SIWEK GT, DODGSON KJ, DE MAGALHAES-SILVERMAN M et al.: Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin. Infect. Dis. (2004) 39(4):584-587.
   PubMed Web of Science ®Google Scholar
• MARTY FM, COSIMI LA, BADEN LR: Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med. (2004) 350(9):950-952.
   PubMed Web of Science ®Google Scholar
• IMHOF A, BALAJEE SA, FREDRICKS DN, ENGLUND JA, MARR KA: Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis. (2004) 39(5):743-746.
   PubMed Web of Science ®Google Scholar
• MATTNER F, WEISSBRODT H, STRUEBER M: Two case reports: fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scand. J. Infect. Dis. (2004) 36(4):312-314.
   PubMed Web of Science ®Google Scholar
• HERBRECHT RMK, CATANZARO A, GREENBERG R et al.: Posaconazole as salvage therapy for invasive fungal infections unresponsive to voriconazole: a case series. 44th Interscience Conference on Antimicrobial agents and Chemotherapy, Washington, DC, USA (October 30 – November 2 2004).
   Google Scholar
• MANAVATHU EK, CUTRIGHT JL, LOEBENBERG D, CHANDRASEKAR PH: A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J. Antimicrob. Chemother. (2000) 46(2):229-234.
   PubMed Web of Science ®Google Scholar
• MOSQUERA J, DENNING DW: Azole cross-resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. (2002) 46(2):556-557.
   PubMed Web of Science ®Google Scholar
• DENNING DW: Echinocandin antifungal drugs. Lancet (2003) 362(9390):1142-1151.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, BOYKEN L et al.: Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J. Clin. Microbiol. (2003) 41(12):5729-5731.
   PubMed Web of Science ®Google Scholar
• ERNST EJ, KLEPSER ME, ERNST ME, MESSER SA, PFALLER MA: In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn. Microbiol. Infect. Dis. (1999) 33(2):75-80.
   PubMed Web of Science ®Google Scholar
• ERNST EJ, KLEPSER ME, PFALLER MA: Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. (2000) 44(4):1108-1111.
   PubMed Web of Science ®Google Scholar
• BOWMAN JC, HICKS PS, KURTZ MB et al.: The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. (2002) 46(9):3001-3012.
   PubMed Web of Science ®Google Scholar
• ULLMANN AJ, LIPTON JH, VESOLE DH et al.: Posaconazole versus fluconazole for prophylaxis of invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients with graft -versus-host disease: results of a multicenter trial. 45th International Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (16 – 19 December 2005).
   Google Scholar
• THIEBAUT SR A, ANTAL M, BREYSSE C, PIVOT C: Refractory invasive fungal infections in patients with hematologic malignancies: combination of new antifungal agents (voriconazole or caspofungin) with amphotericin B. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA (27 – 30 September 2002).
   Google Scholar
• MANAVATHU EK, ALANGADEN GJ, CHANDRASEKAR PH: Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J. Antimicrob. Chemother. (2003) 51(6):1423-1425.
   PubMed Web of Science ®Google Scholar
• PEREA S, GONZALEZ G, FOTHERGILL AW et al.: In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. (2002) 46(9):3039-3041.
   PubMed Web of Science ®Google Scholar
• PETRAITIS V, PETRAITIENE R, SARAFANDI AA et al.: Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis. (2003) 187(12):1834-1843.
   PubMed Web of Science ®Google Scholar
• SINGH N, LIMAYE A, SAFDAR N et al.: Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients. 45th International Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (16 – 19 December 2005).
   Google Scholar